Shuttle Pharmaceuticals (SHPH) announced a sponsored research agreement with the University of California, San Francisco, UCSF, to advance pre-clinical development of Shuttle Diagnostics’ ligand to the prostate-specific membrane antigen, PSMA, as a potential diagnostic and therapeutic, or theranostic, molecule. Theranostic molecules are suitable for diagnosis and therapy of cancers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHPH: